In a filing, Acadia Pharmaceuticals Inc revealed its EVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. unloaded Company’s shares for reported $82728.0 on Sep 15 ’25. In the deal valued at $23.65 per share,3,498 shares were sold. As a result of this transaction, Schneyer Mark C. now holds 43,447 shares worth roughly $1.04 million.
Then, GAROFALO ELIZABETH A. sold 1,600 shares, generating $41,560 in total proceeds. Upon selling the shares at $25.98, the Director now owns 25,382 shares.
Before that, Schneyer Mark C. sold 22,000 shares. Acadia Pharmaceuticals Inc shares valued at $554,024 were divested by the EVP, CHIEF FINANCIAL OFFICER at a price of $25.18 per share. As a result of the transaction, Schneyer Mark C. now holds 40,130 shares, worth roughly $0.96 million.
Deutsche Bank upgraded its Acadia Pharmaceuticals Inc [ACAD] rating to a Buy from a a Hold in a research note published recently. A number of analysts have revised their coverage, including Deutsche Bank’s analysts, who began to cover the stock in mid February with a ‘”a Hold”‘ rating. Guggenheim also remained covering ACAD and has decreased its forecast on January 03, 2025 with a “Neutral” recommendation from previously “Buy” rating.
Price Performance Review of ACAD
On Tuesday, Acadia Pharmaceuticals Inc [NASDAQ:ACAD] saw its stock fall -2.88% to $23.96. Over the last five days, the stock has lost -3.54%. Acadia Pharmaceuticals Inc shares have risen nearly 50.22% since the year began. Nevertheless, the stocks have risen 30.57% over the past one year.
How much short interest is there in Acadia Pharmaceuticals Inc?
A steep rise in short interest was recorded in Acadia Pharmaceuticals Inc stocks on 2025-08-29, dropping by -1.75 million shares to a total of 9.28 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 11.03 million shares. There was a decline of -18.89%, which implies that there is a negative sentiment for the stock.
